Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Fousteris, Evangelos ^a   Melidonis, Andreas ^a   Panoutsopoulos, George ^b   Tzirogiannis, Konstantinos ^a   Foussas, Stefanos ^a   Theodosis Georgilas, Anastasios ^a   Tzerefos, Stavros ^a   Matsagos, Spiridon ^a   Boutati, Eleni ^c   Economopoulos, Theofanis ^c   Dimitriadis, George ^c   Raptis, Sotirios ^c,d  

^a Tzanio General Hospital of Piraeus   (Greece)

^b UNIVERSITY OF PELOPONNESE   (Greece)

^c Attikon University General Hospital   (Greece)

^d Hellenic National Diabetes Center   (Greece)

Author keywords

Bnp; Diastolic dysfunction; Hs crp; Soluble st2; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL MARKER ST2; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INTERLEUKIN 1 RECEPTOR; TOLL LIKE RECEPTOR 1; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IL1RL1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE OVERLOAD; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLE; AGED; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ECHOGRAPHY; GREECE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; UPREGULATION;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GREECE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 81355138191     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-101     Document Type: Article

References (36)

1. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5):721-6. 10.1161/01.CIR.0000047274.66749.FE, 12578875.
2. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106(23):2961-6. 10.1161/01.CIR.0000038705.69871.D9, 1460012, 12460879.
3. Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008, 52(18):1458-65. 10.1016/j.jacc.2008.07.042, 19017513.
4. Pascual-Figal DA, Ordonez-Lianos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A, . MUSIC Investigators Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009, 54(23):2174-9. 10.1016/j.jacc.2009.07.041, 19942089, MUSIC Investigators.
5. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109(18):2186-90. 10.1161/01.CIR.0000127958.21003.5A, 15117853.
6. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010, 55(3):243-50. 10.1016/j.jacc.2009.08.047, 20117403.
7. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117(15):1936-44. 10.1161/CIRCULATIONAHA.107.728022, 18378613.
8. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department Study) study. J Am Coll Cardiol 2007, 50(7):607-13. 10.1016/j.jacc.2007.05.014, 17692745.
9. Januzzi JL, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long term mortality prediction in acutely dyspneic patients. Clin Chem 2010, 56(12):1814-21. 10.1373/clinchem.2010.146506, 20921266.
10. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010, 43(9):714-9. 10.1016/j.clinbiochem.2010.02.002, 20153308.
11. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function and long term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2(4):311-9. 10.1161/CIRCHEARTFAILURE.108.833707, 19808354.
12. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Inteleukin-33-cytokine of dual function or novel alarmin?. Trends Immunol 2009, 30:227-233. 10.1016/j.it.2009.03.003, 19359217.
13. Miller AM. Role of IL-33 in inflammation and disease. Journal of Inflammation 2011, 8:22-34. 10.1186/1476-9255-8-22, 3175149, 21871091.
14. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP. IL-33 reduces macrophage foam cell formation. J Immunology 2010, 185:1222-1229.
15. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Satar N, Baker AH, McInnes IB, Liew FY. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346. 10.1084/jem.20071868, 2271006, 18268038.
16. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117(6):1538-49. 10.1172/JCI30634, 1865027, 17492053.
17. Seki K, Sanada S, Kudinova AY, Steinhauser MI, Handa V, Gannon J, Lee RT. Inteleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691. 10.1161/CIRCHEARTFAILURE.109.873240, 19919994.
18. Schmitz J, Owyang A, Oldhman E, Song Y, Murphy E, McClanahan TK, Zurawski E, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity 2005, 23:479-490. 10.1016/j.immuni.2005.09.015, 16286016.
19. Moulin D, Donze O, Tabalot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of proinflammatory mediators by mast cells. Cytokine 2007, 40:216-225. 10.1016/j.cyto.2007.09.013, 18023358.
20. Brett Chery W, Yoon J, Bartemes KR, Lijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. Journal of Allergy and Clinical Immunology 2008, 121:1484-1490. 10.1016/j.jaci.2008.04.005, 2821937, 18539196.
21. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010, 185:1222-1229.
22. Badawi A, Klip A, Haddad P, Cole D, Bailo BG, Karmali M. Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:173-186.
23. Dehghan A, Kardys I, De Maat MP. Genetic variation, C-reactive protein levels and incidence of diabetes. Diabetes 2007, 56:872-878. 10.2337/db06-0922, 17327459.
24. Lee CC, Adler AI, Sandhu MS. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009, 52:1040-1047. 10.1007/s00125-009-1338-3, 19326095.
25. Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy?. Diabetes Metab 2003, 29(5):455-66. 10.1016/S1262-3636(07)70059-9, 14631322.
26. Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, Felix B, Berneis K, Rickenbacher P. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010, 12(9):951-7. 10.1093/eurjhf/hfq110, 20581103.
27. Vignon-Zellweger N, Relle K, Kienten E, Seider P, Sharkovska J, Heiden S, Kalk P, Schwab K, Albrecht-Kupper B, Theuring F, Stasch JP, Hocher B. Endothelin-1 overexpression restores diastolic function in Enos knockout mice. J Hypertens 2011, 29:961-970. 10.1097/HJH.0b013e3283450770, 21451422.
28. Yndestad A, Marshall AK, Hodgkinson JD, Thamel L, Sugden PH. Clerk A: modulation of interleukin signalling and gene expression in cardiac myocytes by enothelin-1. Int J Biochem Cell Biol 2010, 42:263-272. 10.1016/j.biocel.2009.10.021, 19861169.
29. Beutler BA. TLRs and innate immunity. Blood 2009, 113:1399-1407. 2644070, 18757776.
30. Liu J, Buckley JM, Redmond PH, Wang JH. ST2 Negatively Regulates TLR2 Signaling, but Is Not Required for Bacterial Lipoprotein-Induced Tolerance. The Journal of Immunology 2010, 184:5802-5808. 10.4049/jimmunol.0904127, 20400705.
31. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic C, Campbell C, Xu D, Liew FY. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunology 2001, 166:6633-6639.
32. Takenazo NM, Hayakawa H, Hayakawa S, Aoki S, Yanagisawa H, Endo S, Tominaga S. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006, 341:425-432. 10.1016/j.bbrc.2005.12.206, 16426569.
33. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33 a potent inducer of adaptive immunity to intestinal nematobes. J Immunol 2008, 180:2443-2449.
34. Zdravkovic N, Shahin A, Arsenijevic N, Lukic ML. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Molecular Immunology 2009, 47:28-36. 10.1016/j.molimm.2008.12.023, 19356801.
35. Li J, Jin C, Cleveland JC, Ao L, Xu D, Fullerton DA, Meng X. Enhanced inflammatory responses to toll-like receptor 2/4 stimulation in type 1 diabetic coronary artery endothelial cells: the effect of insulin. Cardiovasc Diabetol 2010, 9:90. 10.1186/1475-2840-9-90, 3018430, 21162749.
36. Foryst-Ludwig A, Hartge M, Clemenz M, Sprang C, Heb K, Marx N. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol 2010, 9:64. 10.1186/1475-2840-9-64, 2984486, 20955583.